CL2013000223A1 - Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion. - Google Patents

Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion.

Info

Publication number
CL2013000223A1
CL2013000223A1 CL2013000223A CL2013000223A CL2013000223A1 CL 2013000223 A1 CL2013000223 A1 CL 2013000223A1 CL 2013000223 A CL2013000223 A CL 2013000223A CL 2013000223 A CL2013000223 A CL 2013000223A CL 2013000223 A1 CL2013000223 A1 CL 2013000223A1
Authority
CL
Chile
Prior art keywords
hmgb1
kit
realization
detection
inflammatory bowel
Prior art date
Application number
CL2013000223A
Other languages
English (en)
Inventor
Salvatore Cucchiara
Laura Stronati
Roberta Vitali
Original Assignee
Dmg Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmg Italia Srl filed Critical Dmg Italia Srl
Publication of CL2013000223A1 publication Critical patent/CL2013000223A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CL2013000223A 2010-08-05 2013-01-23 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion. CL2013000223A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.

Publications (1)

Publication Number Publication Date
CL2013000223A1 true CL2013000223A1 (es) 2014-03-28

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000223A CL2013000223A1 (es) 2010-08-05 2013-01-23 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion.

Country Status (14)

Country Link
US (1) US20130137123A1 (es)
EP (1) EP2601525A1 (es)
JP (1) JP2013534313A (es)
CN (1) CN103069276A (es)
AU (1) AU2011287193B2 (es)
BR (1) BR112013002145A2 (es)
CA (1) CA2807107C (es)
CL (1) CL2013000223A1 (es)
EA (1) EA201390197A1 (es)
IL (1) IL223845A (es)
IT (1) IT1406051B1 (es)
MX (1) MX2013001327A (es)
PE (1) PE20131062A1 (es)
WO (1) WO2012017466A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2901704T3 (es) 2013-03-15 2022-03-23 Protagonist Therapeutics Inc Análogos de hepcidina y usos de los mismos
EP3094973B1 (en) 2013-11-07 2020-07-29 Diagnodus Limited Biomarkers
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018089693A2 (en) * 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
KR20200006108A (ko) 2017-05-12 2020-01-17 에보니크 오퍼레이션즈 게엠베하 동물에서 씨. 퍼프린젠스 유발된 질환을 검출하는 방법
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US12031991B2 (en) 2018-03-02 2024-07-09 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2022109328A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822078B2 (en) * 1996-07-17 2004-11-23 Kaneka Corp. Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
EP1601969A2 (en) * 2003-03-08 2005-12-07 Auvation Ltd Markers for colorectal cancer
WO2007001422A2 (en) * 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
WO2008075788A1 (ja) * 2006-12-20 2008-06-26 Shino-Test Corporation ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬
WO2009017444A2 (en) * 2007-08-02 2009-02-05 Iss Immune System Stimulation Ab Diagnosis, staging and monitoring of inflammatory bowel disease
WO2009114756A2 (en) * 2008-03-14 2009-09-17 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome

Also Published As

Publication number Publication date
MX2013001327A (es) 2013-03-08
ITRM20100442A1 (it) 2012-02-06
IT1406051B1 (it) 2014-02-06
WO2012017466A8 (en) 2013-07-11
EA201390197A1 (ru) 2013-06-28
JP2013534313A (ja) 2013-09-02
WO2012017466A1 (en) 2012-02-09
CA2807107A1 (en) 2012-02-09
AU2011287193A1 (en) 2013-06-13
PE20131062A1 (es) 2013-10-16
CN103069276A (zh) 2013-04-24
CA2807107C (en) 2017-01-03
AU2011287193B2 (en) 2015-08-13
BR112013002145A2 (pt) 2016-05-24
IL223845A (en) 2016-06-30
EP2601525A1 (en) 2013-06-12
US20130137123A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
CL2013000223A1 (es) Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias , metodo no invasivo para deteccion en muestras fecales y kit para su realizacion.
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI1009420A2 (pt) axmi-001, axmi-002, axmi-030, e axmi-045; genes de toxina e métodos para seu uso
BRPI1012340A (pt) proteínas de ligação específica e usos das mesmas
BRPI1012861A2 (pt) catalisador, e, uso do catalisador
BRPI0819956A2 (pt) Métodos e aparelhos de nova seleção celular.
BRPI1011321A2 (pt) dispositivo de monitoramento de analito de métodos de uso
BRPI1014708A2 (pt) dihidropirimidinonas para uso como inibidores de bace2
EP2338989A4 (en) METHOD OF PREPARING AN FECAL SAMPLE, PREPARATION SOLUTION OF AN FECAL SAMPLE, AND KIT FOR COLLECTING FECES
BR112012005736A2 (pt) di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BRPI1014544A8 (pt) anticorpos anti-il-17f e metodos de uso dos mesmos
BRPI0915086A2 (pt) detecção do uso de canabis
BRPI0920891A2 (pt) misturas de alfa-amilase e métodos para uso das referidas misturas
BRPI0924225A2 (pt) linhagens de células que expressam nav e métodos de uso
BRPI1007397A2 (pt) misturas de borrachas, método para a fabricação das misturas de borrachas e seu uso
BR112012005156A2 (pt) poliuretanos hidrossolúveis e utilização de poliuretanos
BRPI1006996A2 (pt) composição, método e uso
BR112012001043A2 (pt) tinturas fluorescentes e uso das mesmas
BRPI0924180A2 (pt) lacases e métodos de uso das mesmas em baixa temperatura
BRPI0920222A2 (pt) composições catalisadoras e métodos de produção e uso das mesmas
BRPI0814988A2 (pt) Hidridização in-situ para detectar marcadores de rna e dna.
BRPI1013671A2 (pt) método para o diagnóstico de endometriose e kit de diagnóstico para endometriose
BRPI1010859A2 (pt) aptâmero para quimase, e uso do mesmo
BR112014012882A2 (pt) método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
BRPI1009460A2 (pt) domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.